Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

Cited by (999)

Items 201–300 of 999

1. Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial
   Ahmed, S. · 2006 · European Heart Journal
2. Medical treatment of obesity: The past, the present and the future
   Bray, George A. · 2014 · Best Practice & Research Clinical Gastroenterology
3. The case for peripheral CB1receptor blockade in the treatment of visceral obesity and its cardiometabolic complications
   George Kunos, Joseph Tam · 2011 · British Journal of Pharmacology
4. Recent Advances in Obesity Pharmacotherapy
   Marcos Alejandro Mayer, Christián Höcht, Ana M. Puyó, Carlos Alberto Taira · 2009 · Current Clinical Pharmacology
5. Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet β-cells via CB1 receptors
   Masanori Nakata, Toshihiko Yada · 2007 · Regulatory Peptides
6. Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations
   Michael Benzinou, Jean-Claude Chèvre, Kirsten J. Ward, Cécile Lecœur, Christian Dina C, Stéphane Lobbens, Emmanuelle Durand, Jérôme Delplanque, Fritz Horber, Barbara Heude et al. · 2008 · Human Molecular Genetics
7. The utility of animal models to evaluate novel anti‐obesity agents
   Steve P. Vickers, Helen C. Jackson, Sharon C. Cheetham · 2011 · British Journal of Pharmacology
8. Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease
   Raed Osman, Philippe L. L’Allier, Nader Z. Elgharib, Jean‐Claude Tardif · 2006 · Vascular Health and Risk Management
9. Nicotine and cannabinoids: parallels, contrasts and interactions
   VIVEROS, M, MARCO, E, FILE, S · 2006 · Neuroscience & Biobehavioral Reviews
10. Alteration of Lipid Profile in Subclinical Hypothyroidism: A Meta-Analysis
    Jian Xu · 2014 · Medical Science Monitor
11. Endocannabinoids and the Control of Energy Homeostasis
    George Kunos, Douglas Osei‐Hyiaman, Jie Liu, Grzegorz Godlewski, Sándor Bátkai · 2008 · Journal of Biological Chemistry
12. Genetic Variations at the Endocannabinoid Type 1 Receptor Gene (CNR1) Are Associated with Obesity Phenotypes in Men
    Paola Russo, Pasquale Strazzullo, Francesco Paolo Cappuccio, David‐Alexandre Trégouët, Fabio Lauria, M. Loguercio, Gianvincenzo Barba, Marco Versiero, Alfonso Siani · 2007 · The Journal of Clinical Endocrinology & Metabolism
13. Adiponectin: a biomarker of obesity-induced insulin resistance in adipose tissue and beyond
    Jin‐Ying Lu, Kuo‐Chin Huang, Lin‐Chau Chang, Ying-Shing Huang, Yu‐Chiao Chi, Ta-Chan Su, Chi‐Ling Chen, Wei‐Shiung Yang · 2008 · Journal of Biomedical Science
14. Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-δ
    Zhen Cheng Yan, Dao Yan Liu, Li Li Zhang, Chen Shen, Qun Li, Ting Bing Cao, Lijuan Wang, Hai Nie, Walter Zidek, Martin Tepel et al. · 2007 · Biochemical and Biophysical Research Communications
15. The obesity epidemic and its cardiovascular consequences
    Agnieszka Behn, Ehud Ur · 2006 · Current Opinion in Cardiology
16. The Cannabinoid CB1 Receptor Antagonist Rimonabant Stimulates 2-Deoxyglucose Uptake in Skeletal Muscle Cells by Regulating the Expression of Phosphatidylinositol-3-kinase
    Iolanda Esposito, Maria Proto, Patrizia Gazzerro, Chiara Laezza, Claudia Miele, Anna Teresa Alberobello, Vittoria D’Esposito, Francesco Bèguinot, Pietro Formisano, Maurizio Bifulco · 2008 · Molecular Pharmacology
17. Pharmacotherapy for obesity
    Mingfang Li, Bernard M.Y. Cheung · 2009 · British Journal of Clinical Pharmacology
18. Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?
    Harold Edward Bays, Lawrence Blonde, Robert S. Rosenson · 2006 · Expert Review of Cardiovascular Therapy
19. Increased Energy Expenditure Contributes More to the Body Weight-Reducing Effect of Rimonabant than Reduced Food Intake in Candy-Fed Wistar Rats
    Andreas W. Herling, Susanne Kilp, Ralf Elvert, Guido Haschke, Werner Kramer · 2008 · Endocrinology
20. Anti-Obesity Effect of the CB2 Receptor Agonist JWH-015 in Diet-Induced Obese Mice
    Aaron N.A. Verty, Aneta Stefanidis, Andrew J. McAinch, Deanne Helena Hryciw, Brian J. Oldfield · 2015 · PLoS ONE
21. Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development
    Thuy Nguyen, Brian F. Thomas, Yanan Zhang · 2019 · Current Topics in Medicinal Chemistry
22. The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high‐fat diet
    Vincenzo Di Marzo, Raffaele Capasso, Isabel Matias, Gabriella Aviello, Stefania Petrosino, Francesca Borrelli, Barbara Romano, Pierangelo Orlando, Francesco Capasso, Angelo Antonio Izzo · 2008 · British Journal of Pharmacology
23. Cannabinoids and Atherosclerotic Coronary Heart Disease
    Sandeep Singla, Rajesh Sachdeva, Jawahar L. Mehta · 2012 · Clinical Cardiology
24. Transcriptional Regulation of Cannabinoid Receptor-1 Expression in the Liver by Retinoic Acid Acting via Retinoic Acid Receptor-γ
    Bani Mukhopadhyay, Jie Liu, Douglas Osei‐Hyiaman, Grzegorz Godlewski, Partha Mukhopadhyay, Lei Wang, Won‐Il Jeong, Bin Gao, Gregg Duester, Ken Mackie et al. · 2010 · Journal of Biological Chemistry
25. Metabolic Syndrome Increases Operative Mortality in Patients Undergoing Coronary Artery Bypass Grafting Surgery
    Najmeddine Echahidi, Philippe Pîbarot, Jean‐Pierre Després, Jean-Marc Daigle, Dania Mohty, Pierre Voisine, Richard G Baillot, Patrick Mathieu · 2007 · Journal of the American College of Cardiology
26. The Role of Adipocyte Insulin Resistance in the Pathogenesis of Obesity-Related Elevations in Endocannabinoids
    Tara M. D'Eon, Kerry A. Pierce, Jeffery J. Roix, Andrew Tyler, Hong Chen, Sandra R. Teixeira · 2008 · Diabetes
27. CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function
    Vedat Tiyerili, Sebastian Zimmer, Suzin Jung, Kerstin Wassmann, Claas P. Naehle, Dieter Lütjohann, Andreas Zimmer, Georg Nickenig, Sven Waßmann · 2010 · Basic Research in Cardiology
28. Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas
    Chen Li, Peter M. Jones, Shanta Jean Persaud · 2010 · Pharmacology & Therapeutics
29. New insights on the role of the endocannabinoid system in the regulation of energy balance
    Blandine Gatta‐Cherifi, Daniela Cota · 2015 · International Journal of Obesity
30. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity
    Foteini Christopoulou, Dimitrios Nikiforos Kiortsis · 2010 · Journal of Clinical Pharmacy and Therapeutics
31. Peripherally restricted CB1 receptor blockers
    Robert J. Chorvat · 2013 · Bioorganic & Medicinal Chemistry Letters
32. Pharmacotherapeutic targeting of the endocannabinoid signaling system: Drugs for obesity and the metabolic syndrome
    Kiran V. Vemuri, David R. Janero, Alexandros Makriyannis · 2007 · Physiology & Behavior
33. The role of insulin resistance in the pathogenesis of atherosclerotic cardiovascular disease: an updated review
    Kota J. Reddy, Manmeet Singh, Joey R. Bangit, Richard R. Batsell · 2010 · Journal of Cardiovascular Medicine
34. Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory
    Clarke, Julia R., Rossato, Janine I., Monteiro, Siomara, Bevilaqua, Lia R.M., Izquierdo, Iván, Cammarota, Martín · 2008 · Neurobiology of Learning and Memory
35. Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome
    Svetlana Slavić, Dilyara Lauer, Manuela Sommerfeld, Ulrich Rudolf Kemnitz, Aleksandra Grzesiak, Manuela Trappiel, Christa Thöne‐Reineke, Johannes Baulmann, Ludovít Paulis, Kai Kappert et al. · 2013 · Journal of Molecular Medicine
36. Human CB1 Receptor Isoforms, present in Hepatocytes and β-cells, are Involved in Regulating Metabolism
    Isabel González‐Mariscal, Susan M. Krzysik-Walker, Maı̀re E. Doyle, Qing‐Rong Liu, Raffaello Cimbro, Sara Santa-Cruz Calvo, Soumita Ghosh, Lukasz M. Ciesla, Ruin Moaddel, Olga D. Carlson et al. · 2016 · Scientific Reports
37. The Expanded Endocannabinoid System/Endocannabinoidome as a Potential Target for Treating Diabetes Mellitus
    Alain Veilleux, Vincenzo Di Marzo, Cristoforo Silvestri · 2019 · Current Diabetes Reports
38. Impact of weight loss on the metabolic syndrome
    Suzanne Phelan, Thomas A. Wadden, Robert I. Berkowitz, David B. Sarwer, Leslie G. Womble, Robert K. Cato, Rebecca A. Rothman · 2007 · International Journal of Obesity
39. Peripheral cannabinoid 1 receptor blockade activates brown adipose tissue and diminishes dyslipidemia and obesity
    Mariëtte R. Boon, Sander Kooijman, Andrea D. van Dam, Leonard R. Pelgrom, Jimmy F.P. Berbée, Cheryl A. R. Visseren, Robin C. Aggele, Anita M. van den Hoek, Hetty C. M. Sips, Marc Lombès et al. · 2014 · The FASEB Journal
40. Allosteric ligands for G protein-coupled receptors: A novel strategy with attractive therapeutic opportunities
    Marco De Amici, Clelia Dallanoce, Ulrike Holzgrabe, Christian Tränkle, Klaus Mohr · 2009 · Medicinal Research Reviews
41. The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from β3-adrenoceptor agonists
    Arch, Jonathan R. S. · 2008 · Naunyn-Schmiedeberg's Archives of Pharmacology
42. Single application of a CB1 receptor antagonist rapidly following head injury prevents long-term hyperexcitability in a rat model
    Julio C. Echegoyen, Caren Armstrong, Robert J. Morgan, Iván Soltész · 2009 · Epilepsy Research
43. Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes
    Nina Perwitz, J. Wenzel, Isabel Viola Wagner, Jürgen Büning, Maren Drenckhan, Kim Zarse, Michael Ristow, W. Lilienthal, Hendrik Lehnert, Johannes Christian Klein · 2009 · Diabetes Obesity and Metabolism
44. Pharmacological treatment and therapeutic perspectives of metabolic syndrome
    Soo Kyung Lim, Robert H. Eckel · 2014 · Reviews in Endocrine and Metabolic Disorders
45. The concept of cardiometabolic risk: Bridging the fields of diabetology and cardiology
    Jean‐Pierre Després, Amélie Cartier, Mélanie Côté, Benoît J. Arsenault · 2008 · Annals of Medicine
46. A neutral CB1 receptor antagonist reduces weight gain in rat
    Adam P. Chambers, Kiran V. Vemuri, Yan Peng, JodiAnne T. Wood, Teresa Olszewska, Quentin J. Pittman, Alexandros Makriyannis, Keith A. Sharkey · 2007 · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
47. Current and emerging therapies for managing hyperphagia and obesity in Prader‐Willi syndrome: A narrative review
    Qiming Tan, Camila E. Orsso, Edward C. Deehan, Lucila Triador, Catherine J. Field, Hein Min Tun, Joan C. Han, Timo D. Müller, Andrea Maria Haqq · 2019 · Obesity Reviews
48. Chronic 5‐HT 6 receptor modulation by E‐6837 induces hypophagia and sustained weight loss in diet‐induced obese rats
    Angels Fisas, Xavier Codony, Gonzalo Romero, Alberto Dordal, Jesús Giraldo, Ramon Mercè, Jörg Holenz, David J. Heal, Helmut Buschmann, Petrus J. Pauwels · 2006 · British Journal of Pharmacology
49. A critical review of the cannabinoid receptor as a drug target for obesity management
    Fahri Akbaş, Christoph Gasteyger, Anders Mikael Sjödin, Arne Vernon Astrup, Thomas Meinert Larsen · 2008 · Obesity Reviews
50. The endocannabinoid system as a target for the treatment of cannabis dependence
    Jason R. Clapper, Regina A. Mangieri, Daniele Piomelli · 2008 · Neuropharmacology
51. Obesity and reproduction: an educational bulletin
    2008 · Fertility and Sterility
52. Energy balance regulation by endocannabinoids at central and peripheral levels
    Carmelo Quarta, Roberta Mazza, Silvana Obici, Renato Pasquali, Uberto Pagotto · 2011 · Trends in Molecular Medicine
53. CB1 receptor antagonism: biological basis for metabolic effects
    Vincenzo Di Marzo · 2008 · Drug Discovery Today
54. Cannabinoids Stimulate Fibroblastic Colony Formation by Bone Marrow Cells Indirectly via CB2 Receptors
    Andy M. Scutt, Elizabeth M. Williamson · 2007 · Calcified Tissue International
55. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study
    Louis J. Aronne, Serena Tonstad, Manuel Moreno, Ira Gantz, Ngozi Erondu, S Suryawanshi, Cliona M. Molony, Solveig K. Sieberts, J. Nayee, A G Meehan et al. · 2010 · International Journal of Obesity
56. Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis
    A. N. Fabricatore, Thomas A. Wadden, Reneé H. Moore, Meghan L. Butryn, E. A. Gravallese, Ngozi Erondu, Steven B. Heymsfield, Allison Martin Nguyen · 2009 · Obesity Reviews
57. The Obesity Epidemic: Current and Future Pharmacological Treatments
    Karl G. Hofbauer, Janet R. Nicholson, Olivier Boss · 2006 · The Annual Review of Pharmacology and Toxicology
58. Pharmacotherapy of Childhood Obesity
    Michael Freemark · 2007 · Diabetes Care
59. Exenatide prevents fat‐induced insulin resistance and raises adiponectin expression and plasma levels
    L. Li, Gangyi Yang, Q. Li, Xu Tan, Hongfei Liu, Yi Tang, G. Boden · 2008 · Diabetes Obesity and Metabolism
60. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity
    Carlos Eduardo Leite, Clei Angelo Mocelin, Guilherme Oliveira Petersen, Mirna Bainy Leal, Flávia Valladão Thiesen · 2009 · Pharmacological Reports
61. The role of the endocannabinoid system in lipogenesis and fatty acid metabolism
    Roberto Vettor, Claudio Pagano · 2009 · Best Practice & Research Clinical Endocrinology & Metabolism
62. Diet and nutrition in polycystic ovary syndrome (PCOS): Pointers for nutritional management
    Farshchi, H., Rane, A., Love, A., Kennedy, R. L. · 2007 · Journal of Obstetrics and Gynaecology
63. Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers
    Jamie Horder, Catherine J. Harmer, Philip J. Cowen, Ciara McCabe · 2010 · The International Journal of Neuropsychopharmacology
64. Lifestyle Intervention and Coronary Heart Disease Risk Factor Changes over 18 Months in Postmenopausal Women: The Women On the Move through Activity And Nutrition (WOMAN Study) Clinical Trial
    Lewis H. Kuller, Laura S. Kinzel, Kelley Pettee Gabriel, Andrea M. Kriska, Laurey R. Simkin‐Silverman, Molly B. Conroy, Frani M. Averbach, William Scott Pappert, B. Delia Johnson · 2006 · Journal of Women s Health
65. The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome
    Martin Storr, B Yüce, Christopher N. Andrews, Keith A. Sharkey · 2008 · Neurogastroenterology & Motility
66. Growth Hormone Secretagogue Receptor Dimers: A New Pharmacological Target
    Martin K. Wellman, Alfonso B. Abizaid · 2015 · eNeuro
67. Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: Comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142
    Kelly S. Sink, Kristen N. Segovia, Jacquelyn R. Sink, Patrick A. Randall, Lyndsey E. Collins, Mercè Correa, E.J. Markus, Kiran V. Vemuri, Alexandros Makriyannis, John D. Salamone · 2009 · European Neuropsychopharmacology
68. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta‐analysis
    Kari Johansson, Kristian Neovius, Stacia M. DeSantis, Stephan Rössner, Martin Neovius · 2009 · Obesity Reviews
69. Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis
    Reşat Çınar, Malliga R. Iyer, Ziyi Liu, Zongxian Cao, Tony Jourdan, Katalin Erdélyi, Grzegorz Godlewski, Gergő Szanda, Jie Liu, Joshua K. Park et al. · 2016 · JCI Insight
70. Effect of anti-obesity drug on cardiovascular risk factors: A systematic review and meta-analysis of randomized controlled trials
    Zhou, Yu-Hao, Ma, Xiu-Qiang, Wu, Cheng, Lu, Jian, Zhang, Shan-Shan, Guo, Jia, Wu, Shun-Quan, Ye, Xiao-Fei, Xu, Jin-Fang, He, Jia · 2012 · PLoS ONE
71. Multiple endocannabinoid-mediated mechanisms in the regulation of energy homeostasis in brain and peripheral tissues
    Iñigo Ruı́z de Azúa, Beat Lutz · 2018 · Cellular and Molecular Life Sciences
72. Constitutive Activity at the Cannabinoid CB 1 Receptor Is Required for Behavioral Response to Noxious Chemical Stimulation of TRPV1: Antinociceptive Actions of CB1 Inverse Agonists
    Beatriz Fioravanti, Milena De Felice, Cheryl L. Stucky, Karen A. Medler, Miaw-Chyi Luo, Luis R. Gardell, Mohab M. Ibrahim, T. Philip Malan, Henry I. Yamamura, Michael H. Ossipov et al. · 2008 · Journal of Neuroscience
73. Targeting the adiponectin leptin ratio for postmenopausal breast cancer prevention
    Margot P. Cleary · 2009 · Frontiers in Bioscience-Scholar
74. The endocannabinoid system: Overview of an emerging multi-faceted therapeutic target
    Dipanjan Chanda, Dietbert Neumann, Jan F. C. Glatz · 2018 · Prostaglandins Leukotrienes and Essential Fatty Acids
75. Personalized medicine can pave the way for the safe use of CB1 receptor antagonists
    Judit Lazáry, Gabriella Juhász, László Hunyady, György Bagdy · 2011 · Trends in Pharmacological Sciences
76. Management issues in the metabolic syndrome.
    PRAKASH C. DEEDWANIA, Rajeev Gupta · 2006 · PubMed
77. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1receptor antagonism ? or inverse agonism ? as potential obesity treatment and other therapeutic use
    Shan Xie, M. A. Furjanic, Jarrod Ferrara, N. R. McAndrew, E. L. Ardino, A. Ngondara, Y. Bernstein, K. J. Thomas, E. Kim, J. M. Walker et al. · 2007 · Journal of Clinical Pharmacy and Therapeutics
78. The Role of the Endocannabinoid System in the Regulation of Hypothalamic‐Pituitary‐Adrenal Axis Activity
    Daniela Cota · 2008 · Journal of Neuroendocrinology
79. Bariatric surgery and prevention of cardiovascular events and mortality in morbid obesity: Mechanisms of action and choice of surgery
    Augusto Boido, Valerio Ceriani, Francesco Cetta, Federico Lombardi, Antonio Ettore Pontiroli · 2015 · Nutrition Metabolism and Cardiovascular Diseases
80. Perspectives on Treatment for Nonalcoholic Steatohepatitis
    Guillaume Lassailly, Robert J. Caiazzo, François N. Pattou, Philippe Mathurin · 2016 · Gastroenterology
81. The Neurobiology of Binge-eating Disorder Compared with Obesity: Implications for Differential Therapeutics
    Rebecca G. Boswell, Marc Nicholas Potenza, Carlos M. Grilo · 2020 · Clinical Therapeutics
82. Anti-obesity effects of small molecule melanin-concentrating hormone receptor1 (MCHR1) antagonists
    David R. Luthin · 2007 · Life Sciences
83. HDL Cholesterol: Physiology, Pathophysiology, and Management
    Jeffrey J. Link, Anand K. Rohatgi, James A. de Lemos · 2007 · Current Problems in Cardiology
84. Guías de práctica clínica para el tratamiento de la hipertensión arterial 2007
    Grupo de Trabajo para el Tratamiento de la Hipertensión Arterial de la Sociedad Europea de Hipertensión (ESH), de la Sociedad Europea de Cardiología · 2007 · Revista Española de Cardiología
85. Mechanisms of adiponectin regulation and use as a pharmacological target
    Susan A. Phillips, Jacqueline Kung · 2010 · Current Opinion in Pharmacology
86. Endocrine Functions of Adipose Tissue: Focus on Adiponectin
    James R. Sowers · 2008 · Clinical cornerstone
87. Peripheral cannabinoid-1 receptor blockade restores hypothalamic leptin signaling
    Joseph Tam, Gergő Szanda, Adi Drori, Ziyi Liu, Reşat Çınar, Yoshihiro Kashiwaya, Marc L. Reitman, George Kunos · 2017 · Molecular Metabolism
88. Prolyl Hydroxylase Domain Protein 2 Plays a Critical Role in Diet-Induced Obesity and Glucose Intolerance
    Matsuura, Hirohide, Ichiki, Toshihiro, Inoue, Eriko, Nomura, Masatoshi, Miyazaki, Ryohei, Hashimoto, Toru, Ikeda, Jiro, Takayanagi, Ryoichi, Fong, Guo-Hua, Sunagawa, Kenji · 2013 · Circulation
89. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders
    Cristoforo Silvestri, Vincenzo Di Marzo · 2012 · Expert Opinion on Investigational Drugs
90. Fat to treat fat: Emerging relationship between dietary PUFA, endocannabinoids, and obesity
    Jeffrey J. Kim, Yong Li, Bruce A. Watkins · 2013 · Prostaglandins & Other Lipid Mediators
91. Release of anandamide from blood cells
    Michael Vogeser, Daniela Hauer, Shahnaz Christina Azad, Erasmus Huber, Martin Storr, Gustav Schelling · 2006 · Clinical Chemistry and Laboratory Medicine (CCLM)
92. CB2: Therapeutic target-in-waiting
    Brady K. Atwood, Alex J. Straiker, Ken Mackie · 2011 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
93. Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks
    Kishore M. Gadde, David B. Allison · 2006 · Circulation
94. Are there specific treatments for the metabolic syndrome?
    Dario Giugliano, Antonio Ceriello, Katherine Esposito · 2008 · American Journal of Clinical Nutrition
95. Cannabinoid receptors in acute and chronic complications of atherosclerosis
    François Mach, Fabrizio Montecucco, Sabine Steffens · 2007 · British Journal of Pharmacology
96. Loss of Cannabinoid Receptor CB1 Induces Preterm Birth
    Haibin Wang, Huirong Xie, Sudhansu K. Dey · 2008 · PLoS ONE
97. Cannabis Use and Obesity and Young Adults
    Mohammad Reza Hayatbakhsh, Michael J. O'Callaghan, Abdullah Al Mamun, Gail M. Williams, Alexandra Marie Clavarino, Jake Moses Najman · 2010 · The American Journal of Drug and Alcohol Abuse
98. Obesity and kidney disease
    Mauro Cignarelli, Olga Lamacchia · 2007 · Nutrition Metabolism and Cardiovascular Diseases
99. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader–Willi syndrome
    Ibrahim Knani, Brian James Earley, Shiran Udi, Alina Nemirovski, Rivka Hadar, Asaad Gammal, Reşat Çınar, Harry J. Hirsch, Yehuda Pollak, Itai Gross et al. · 2016 · Molecular Metabolism
100. Rimonabant: Just an Antiobesity Drug? Current Evidence on Its Pleiotropic Effects
     Maurizio Bifulco, Claudia Grimaldi, Patrizia Gazzerro, Simona Pisanti, Antonietta Santoro · 2007 · Molecular Pharmacology